S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Fate Therapeutics Insider Trades

-1.15 (-3.00%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.68 million shs
Average Volume
1.41 million shs
Market Capitalization
$3.55 billion
P/E Ratio
Dividend Yield

Fate Therapeutics (NASDAQ:FATE) Insider Buying and Selling Activity

Insider Ownership

Number Of
Insiders Buying
(Last 12 Months)

Number Of
Insiders Selling
(Last 12 Months)

Amount Of
Insider Selling
(Last 12 Months)
$26.62 M

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get FATE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Fate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Fate Therapeutics (NASDAQ FATE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2022Edward J Dulac IIICFOSell1,770$48.45$85,756.50  
1/11/2022Yu-Waye ChuVPSell3,965$48.51$192,342.15  
1/10/2022Bahram ValamehrInsiderSell5,596$46.38$259,542.48  
1/10/2022Cindy TahlGeneral CounselSell7,738$46.43$359,275.34  
1/10/2022J Scott WolchkoCEOSell34,156$46.86$1,600,550.16  
12/20/2021Edward J Dulac IIICFOSell15,977$60.00$958,620.00  
12/13/2021Bahram ValamehrInsiderSell25,000$47.66$1,191,500.00  
12/10/2021Yu-Waye ChuVPSell7,500$51.46$385,950.00  
11/18/2021J Scott WolchkoCEOSell20,000$54.27$1,085,400.00  
10/21/2021J Scott WolchkoCEOSell30,000$60.22$1,806,600.00  
10/1/2021Cindy TahlGeneral CounselSell50,000$58.83$2,941,500.00  
9/28/2021Edward J Dulac IIICFOSell19,460$62.53$1,216,833.80  
8/19/2021Edward J Dulac IIICFOSell3,474$88.26$306,615.2456,076  
8/19/2021J Scott WolchkoCEOSell20,000$88.01$1,760,200.00  
7/22/2021J Scott WolchkoCEOSell30,000$86.05$2,581,500.00  
6/14/2021Bahram ValamehrInsiderSell25,000$89.32$2,233,000.00111,896  
4/23/2021J Scott WolchkoCEOSell30,000$85.24$2,557,200.00423,793  
4/16/2021Yu-Waye ChuVPSell3,275$83.30$272,807.5067,200  
4/1/2021Cindy TahlInsiderSell30,000$83.81$2,514,300.00136,197  
3/15/2021Bahram ValamehrInsiderSell25,000$92.35$2,308,750.00120,740  
1/21/2021J Scott WolchkoCEOSell30,000$103.05$3,091,500.00393,793  
1/19/2021Cindy TahlGeneral CounselSell35,000$114.76$4,016,600.00125,035  
1/11/2021Cindy TahlGeneral CounselSell9,483$114.94$1,089,976.0296,763  
1/11/2021Daniel D ShoemakerInsiderSell9,482$114.95$1,089,955.9090,336  
1/11/2021J Scott WolchkoCEOSell69,407$116.33$8,074,116.31393,065  
1/8/2021Bahram ValamehrInsiderSell6,230$117.10$729,533.0084,455  
1/8/2021Cindy TahlGeneral CounselSell6,229$117.10$729,415.9096,763  
1/8/2021J Scott WolchkoCEOSell60,820$117.10$7,122,022.00393,065  
1/8/2021Redmile Group, LlcDirectorBuy327,485$85.50$27,999,967.50  
11/16/2020Daniel D ShoemakerInsiderSell25,000$51.83$1,295,750.00113,159  
11/13/2020J Scott WolchkoCEOSell60,000$51.87$3,112,200.00
10/16/2020Cindy TahlGeneral CounselSell29,199$50.25$1,467,249.75128,717  
6/11/2020Redmile Group, LlcDirectorBuy1,412,928$28.31$39,999,991.68  
1/30/2020J Scott WolchkoCEOSell25,000$25.45$636,250.00444,969  
1/8/2020Bahram ValamehrInsiderSell5,700$20.69$117,933.0091,758  
12/20/2019J Scott WolchkoCEOSell25,000$20.17$504,250.00378,969  
10/15/2019Bahram ValamehrInsiderSell6,200$14.18$87,916.00  
10/15/2019Cindy TahlGeneral CounselSell10,200$14.24$145,248.00  
10/15/2019J Scott WolchkoCEOSell21,017$14.44$303,485.48  
9/16/2019Redmile Group, LlcDirectorBuy857,143$17.50$15,000,002.50  
8/1/2019Amir NashatDirectorSell62,005$22.53$1,396,972.65  
7/30/2019Amir NashatDirectorSell118,333$22.51$2,663,675.83  
7/26/2019Amir NashatDirectorSell27,829$22.50$626,152.50  
7/24/2019Amir NashatDirectorSell81,899$22.51$1,843,546.49  
7/22/2019Amir NashatDirectorSell71,166$22.52$1,602,658.32  
7/18/2019Amir NashatDirectorSell21,409$22.50$481,702.50  
6/27/2019Daniel D ShoemakerInsiderSell12,500$20.21$252,625.00148,091  
5/16/2019J Scott WolchkoInsiderSell14,335$19.37$277,668.95389,216  
4/17/2019J Scott WolchkoCEOSell8,541$16.17$138,107.97375,973  
3/28/2019Daniel D ShoemakerInsiderSell12,500$16.94$211,750.00148,091  
3/21/2019J Scott WolchkoInsiderSell20,000$17.61$352,200.00  
3/1/2019Cindy TahlGeneral CounselSell25,000$16.15$403,750.00115,418  
2/25/2019Cindy TahlGeneral CounselSell25,000$16.07$401,750.00115,418  
1/30/2019Amir NashatDirectorSell53,017$14.16$750,720.72  
1/28/2019Amir NashatDirectorSell70,000$13.78$964,600.00  
1/25/2019Amir NashatDirectorSell90,000$14.14$1,272,600.00  
1/18/2019Amir NashatDirectorSell39,483$16.28$642,783.24  
1/7/2019Cindy TahlGeneral CounselSell25,000$16.00$400,000.0047,426  
12/19/2018Amir NashatDirectorSell91,210$13.40$1,222,214.00  
12/13/2018Amir NashatDirectorSell17,788$16.67$296,525.96  
12/11/2018Amir NashatDirectorSell82,528$16.71$1,379,042.88  
9/25/2018Redmile Group, LlcDirectorBuy3,703,704$13.50$50,000,004.00  
10/16/2017Cindy TahlGeneral CounselSell8,091$3.85$31,150.35  
10/16/2017Daniel D ShoemakerInsiderSell13,225$3.87$51,180.75  
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.389,090  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00  
(Data available from 1/1/2013 forward)

Fate Therapeutics (NASDAQ:FATE) Insider Trade Frequently Asked Questions

Who is on Fate Therapeutics's Insider Roster?

The list of insiders at Fate Therapeutics includes Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, Redmile Group, Llc, and Yu-Waye Chu.Learn more on FATE's insiders

What percentage of Fate Therapeutics stock is owned by insiders?

18.58% of Fate Therapeutics stock is owned by insiders. Learn more on FATE's insider holdings

Which Fate Therapeutics insiders have been buying company stock?

The following insider purchased Fate Therapeutics stock in the last 24 months: Redmile Group, Llc ($67,999,959.18).

How much insider buying is happening at Fate Therapeutics?

Insiders have purchased a total of 1,740,413 Fate Therapeutics shares in the last 24 months for a total of $67,999,959.18 bought.

Which Fate Therapeutics insiders have been selling company stock?

The following insiders have sold Fate Therapeutics stock in the last 24 months: Bahram Valamehr ($6,722,325.48), Cindy Tahl ($13,118,317.01), Daniel D Shoemaker ($2,385,705.90), Edward J Dulac III ($2,567,825.54), J Scott Wolchko ($33,427,538.47), and Yu-Waye Chu ($851,099.65).

How much insider selling is happening at Fate Therapeutics?

Insiders have sold a total of 753,761 Fate Therapeutics shares in the last 24 months for a total of $59,072,812.05 sold.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.